Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem, Inc. (Verastem Oncology, Nasdaq: VSTM) is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, and its news flow reflects both commercial progress and active clinical development. Company press releases emphasize the U.S. launch and ongoing adoption of AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer, as well as updates on confirmatory and expansion trials built around this therapy.
Investors following VSTM news can expect regular updates on clinical trial milestones, including the Phase 3 RAMP 301 confirmatory study in recurrent LGSOC, the RAMP 205 trial in first-line metastatic pancreatic cancer, and the now-discontinued RAMP 203 study in KRAS G12C-mutated NSCLC. Verastem also issues detailed communications on early-stage programs such as VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, covering dose-escalation progress, preliminary safety and efficacy signals, and combination strategies with agents like cetuximab.
Beyond clinical data, Verastem’s news includes capital markets events such as public offerings of common stock and pre-funded warrants, as well as corporate updates on leadership changes and participation in healthcare and investor conferences. These announcements provide context on how the company is funding and prioritizing its RAS/MAPK-focused portfolio.
Stock Titan’s VSTM news page aggregates these company-issued releases and related coverage into a single, organized feed. Readers can use this page to track developments in AVMAPKI FAKZYNJA CO-PACK commercialization, monitor progress of key trials like RAMP 301 and VS-7375-101, and follow Verastem’s financing and strategic communications over time.
Verastem Oncology (NASDAQ: VSTM), STAAR Low-Grade Serous Ovarian Cancer Foundation, and Not These Ovaries launched the LGSOC Resource Guide on May 8, 2026 for World Ovarian Cancer Day. Available at www.LGSOCAwarenessDay.org, the guide aggregates educational materials, community resources, and advocacy content for patients, caregivers, and clinicians focused on low-grade serous ovarian cancer.
The guide compiles resources from dozens of organizations, covers diagnosis, treatment, fertility, survivorship, and caregiver support, and notes that content may become outdated as research evolves.
Verastem Oncology (Nasdaq: VSTM) reported Q1 2026 results and program updates on May 7, 2026. Net product revenue was $18.7M. Cash, cash equivalents and investments totaled $181.7M with an expected runway into the first half of 2027. The company initiated three Phase 2 TARGET-D trials for VS-7375 and expects TARGET-D 101 early data in 1H 2026 and mature data in 2H 2026.
RAMP 201J in Japan showed a confirmed ORR of 38% (57% in KRAS-mutant patients). Operating expenses and R&D increased in Q1.
Verastem Oncology (Nasdaq: VSTM) launched the Reimagine Recurrent LGSOC campaign to raise HCP and patient awareness of AVMAPKI FAKZYNJA CO-PACK (avutometinib; defactinib). The campaign highlights the FDA accelerated approval as the first and only therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy, and offers HCP and patient resources, educational tools, and dedicated websites.
Verastem Oncology (Nasdaq: VSTM) will report first quarter 2026 financial results and host a conference call and webcast on Thursday, May 7, 2026 at 4:30 PM ET.
A live audio webcast with accompanying slides will be available under Events & Presentations on the company investor website, with a replay archived after the event.
Verastem Oncology (NASDAQ: VSTM) reported two-year median follow-up data from the Phase 2 RAMP 201 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
With a median follow-up of 24.9 months, key efficacy measures remained consistent with the primary analysis: mDoR was 31.1 months in KRAS-mutant patients, mPFS reached 19.6 months in KRAS-mutant patients, and a 12% discontinuation rate due to adverse events was observed. Fifty percent of KRAS-mutated and 30% of KRAS wild-type patients stayed on therapy for over one year. No new safety signals were reported.
Verastem Oncology (Nasdaq: VSTM) granted 141,000 restricted stock units to eleven new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4) on April 2, 2026. The RSUs vest 25% on the one-year hire anniversary, with the remainder vesting quarterly over the following three years, subject to continued service.
Verastem Oncology (Nasdaq: VSTM) announced multiple abstracts accepted for presentation at the AACR Annual Meeting, April 17-22, 2026, including late-breaking data released April 17. Preclinical results show the oral KRAS G12D dual ON/OFF inhibitor VS-7375 produced deeper, sustained tumor regressions versus ON-only RAS inhibitors across pancreatic, lung, and colorectal models.
In KP4 pancreatic xenografts, VS-7375 maintained mean tumor volume ~80 mm by day 30 versus >850 mm for comparator ON-only inhibitors, and VS-7375 showed strong activity combined with PRMT5 inhibition in MTAP-deleted models.
Verastem Oncology (Nasdaq: VSTM) will present long-term Phase 2 RAMP 201 data on the AVMAPKI FAKZYNJA combination (avutometinib capsules; defactinib tablets) at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers, April 10-13, 2026 in San Juan, Puerto Rico.
The plenary oral presentation on April 10 includes an additional year of follow-up versus the initial report and discusses long-term safety and efficacy in recurrent low-grade serous ovarian cancer patients with and without KRAS mutations. Verastem will also present posters and host an exhibit booth (#608).
Verastem Oncology (Nasdaq: VSTM) reported Q4 2025 net product revenues of $17.5M and full-year 2025 revenues of $30.9M following accelerated FDA approval of AVMAPKI FAKZYNJA CO-PACK in May 2025. The company reported cash, cash equivalents, and investments of $205M (pro forma $234.4M) and expects runway into H1 2027. VS-7375, an oral KRAS G12D inhibitor, cleared multiple dose levels with no DLTs and will progress toward Phase 2 registration-directed trials in PDAC, NSCLC and CRC combination plans.
R&D and SG&A rose materially; key milestones include RAMP 301 topline mid-2027 and VS-7375 early data in 1H 2026.
Verastem Oncology (Nasdaq: VSTM) will report its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026 at 4:30 PM ET. The company will host a conference call and live webcast covering results and business updates.
Investors can join by phone with passcode 7321921 or access a live audio webcast and slides via the Company's Investor Events page; a replay will be archived after the event.